The microbiota provides essential roles in normal physiology such as vitamin synthesis, digestion, and immunity. Bacteria that make up the human microbiota in the gut out number human cells 10:1 and it has been shown that alterations in the gut microbiome are associated with functional gastrointestinal disorders (FGID), obesity, diabetes and cancer. Through microbiota research emerging strategies to treat FGID such as the use of pre- and pro-biotics, antibiotics and faecal microbiota transplants (FMT) are bringing new options for patients and providers dealing with chronic digestive disorders.

Identifying and Characterising Dysbiosis

Historically the classification of Functional Gastrointestinal disorders has been entirely symptom based according to the prevailing bowel habit but this often leads to uncertainty in diagnosis and increases the likelihood of an unnecessary referral for specialist investigation.

16S rRNA microbiota profiling demonstrates both quantitative and qualitative changes of mucosal and faecal gut microbiota, particularly in IBS.

 

BIOHIT now offers the first CE marked test that identifies and characterises gut bacteria by exploiting constant and variable DNA sequences within the 16S rRNA gene, a gene common to all bacteria.

  • Compare the degree of Dysbiosis between different patient groups

  • Monitor changes in the microbiota before and after intervention

  • Assess the Microbiota to predict response to treatment

GA-Map Dysbiosis Test - Service Laboratory test

Product Code

2704

Clinical Background

Index

© 2018 BIOHIT HealthCare Ltd

Contact Us

BIOHIT HealthCare Ltd

Pioneer House, Pioneer Business Park

North Road

Ellesmere Port

Cheshire CH65 1AD

United Kingdom

Tel: +44 151 550 4 550

Fax: +44 151 550 4 551

cs@biohithealthcare.co.uk

  • Twitter Social Icon